Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P10415 (
Bcl-2
)
33,771
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
High-grade B-cell lymphomas, whether originated in a lymph node or in mucosa-associated lymphoid tissue (MALT), show similar morphologic traits, a fact that has fueled a long-running controversy about whether they represent different entities. They differ, however, in that some high-grade MALT lymphomas show less aggressive clinical behavior, a focal low-grade component being identified in some of them. In a search for
bcl-2
protein expression, we have found a significant difference between nodal (39/48) and MALT high-grade B-cell lymphoma (1/15) (P less than 0.01).
Bcl-2
gene product is an inner mitochondrial membrane protein able to give a survival advantage to B-cell lines by blocking programmed cell death. This protein is usually expressed by memory or resting B cells, most activated B cells being
bcl-2
negative, except in lymph-node-originated high-grade B-cell lymphomas, which appear to be mainly
bcl-2
positive. Presence of
bcl-2
protein in nodal large-cell lymphomas seems to be independent of a t(14;18) translocation, only being found in 19 to 28% of these lymphomas, although it constitutes a definite difference between both tumors, suggesting the existence of different molecular genetic characteristics and pathogenesis, and is possibly related to the more aggressive clinical behavior of nodal high-grade tumors.
...
PMID:Different bcl-2 protein expression in high-grade B-cell lymphomas derived from lymph node or mucosa-associated lymphoid tissue. 195 37
In t(14;18) (q32;q21) lymphomas,
bcl-2
gene is activated by the juxtaposition of immunoglobulin (Ig) gene. The fused
bcl-2
-Ig gene generates chimeric mRNAs which consist of
bcl-2
at 5' portion and Ig at 3' portion. Chimeric mRNA does not disrupt the
bcl-2
coding frame of 239 amino acid polypeptide.
Bcl-2
-Ig transgenic mice demonstrated the extended B cell survival and the follicular lymphoproliferation, but they did not develop a malignancy until 25 weeks. Ten percent of them, however, developed malignant diffuse large-cell lymphomas after a long latency. Forty percent of these malignancies demonstrated the c-myc rearrangement, indicating that multiple step changes are required for malignant transformation in
bcl-2
activated cells. Study on the
bcl-2
gene rearrangement in Japanese B cell lymphoma and B-CLL revealed that 10 out of 32 cases of follicular lymphoma (31%), 5 out of 56 cases of diffuse lymphoma (9%) and 2 out of 30 cases of B-CLL (7%) were rearranged. Less frequency of B cell lymphoma, particularly follicular lymphoma in Japan might be partly due to the less
bcl-2
involvement than in American cases. The ratio of
bcl-2
involvement in B-CLL is not significantly different between Japan and U.S.A..
bcl-2
rearrangement at 5' promoter region is noted for Japanese B-CLL which was demonstrated for American cases. The clinical application of polymerase chain reaction for
bcl-2
translocation was also discussed.
...
PMID:[BCL-2 gene in lymphocytic malignancy]. 205 69
The
bcl-2
gene is consistently associated with t(14; 18) chromosomal translocations observed in a large fraction of human B-cell lymphomas. The t(14; 18) translocation results in deregulated expression of the
bcl-2
gene and synthesis of inappropriately high levels of the
Bcl-2
protein. Gene transfer studies suggest a role for
Bcl-2
in cell survival, growth enhancement and oncogenic transformation. To test the suggestion that GTP-binding by
Bcl-2
may mediate its biological effects we characterized the GTP-binding proteins in lymphoid cells expressing
Bcl-2
. Expression of several small GTP-binding proteins was found to be ubiquitous and did not vary with levels of
Bcl-2
. By using immunological, electrophoretic and cell-fractionation techniques, we separated
Bcl-2
from G proteins of small relative molecular mass (Mr) and showed that it is incapable of binding GTP. Our results show that small Mr G proteins are widely expressed in lymphoid cells and that
Bcl-2
is not a novel member of this GTP-binding protein family.
...
PMID:Small G proteins are expressed ubiquitously in lymphoid cells and do not correspond to Bcl-2. 211 53
The t(14; 18) chromosomal translocation of human follicular B-cell lymphoma juxtaposes the
bcl-2
gene with the immunoglobulin heavy chain locus. The
bcl-2
immunoglobulin fusion gene is markedly deregulated resulting in inappropriately elevated levels of
bcl-2
RNA and protein. Transgenic mice bearing a
bcl-2
immunoglobulin minigene demonstrate a polyclonal expansion of resting yet responsive IgM-IgD B cells which display prolonged cell survival but no increase in cell cycling. Moreover, deregulated
bcl-2
extends the survival of certain haematopoietic cell lines following growth-factor deprivation. By using immunolocalization studies we now demonstrate that
Bcl-2
is an integral inner mitochondrial membrane protein of relative molecular mass 25,000 (25k). Overexpression of
Bcl-2
blocks the apoptotic death of a pro-B-lymphocyte cell line. Thus,
Bcl-2
is unique among proto-oncogenes, being localized to mitochondria and interfering with programmed cell death independent of promoting cell division.
...
PMID:Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. 225 Jul 5
Little is known about the biochemical or functional nature of the proteins encoded by the
bcl-2
gene, which undergoes chromosomal translocation in approximately 85% of follicular lymphoma, 20% of diffuse large cell lymphoma and 10% of chronic lymphocytic leukaemia of B cells. Translocation of
bcl-2
sequences from chromosome 18 to the JH segment of the immunoglobulin gene at chromosome band 14q32 in B cells results in deregulated expression of this gene, causing high steady state levels of
bcl-2
messenger RNA2. DNA sequence data indicate that
bcl-2
encodes two proteins by virtue of alternative splicing, designated as
Bcl-2
alpha and
Bcl-2
beta, with relative molecular masses of 26,000 and 22,000 respectively. Cell fractionation experiments indicate that the
bcl-2
alpha gene product is located at the inner surface of the cell membrane, suggesting a possible role in mitogenic signal transduction. We report here that
Bcl-2
alpha has GTP-binding activity and a protein sequence that suggests it belongs to the small molecular weight GTP-binding protein (G protein) family.
...
PMID:The bcl-2 gene encodes a novel G protein. 247 90
Immunohistochemical and molecular genetic studies were performed on tissues involved by follicular lymphomas that at some point in their course showed a lack of detectable surface or cytoplasmic immunoglobulins (Ig). The variable nature of Ig expression in these lymphomas was evidenced by three tumors biopsied from two different sites that showed an Ig-negative phenotype in one biopsy versus an Ig-positive phenotype in the other. The B lineage derivation of Ig-negative follicular lymphomas was confirmed by the presence of Ig heavy and light chain gene rearrangements in eight of eight lymphomas tested. In a way similar to Ig-expressing follicular lymphomas, the Ig-negative tumors were characterized by
bcl-2
gene rearrangements (seven of eight) and overexpression of the
Bcl-2
protein (eight out of nine). In two of the three lymphomas with Ig-positive and Ig-negative tumor cell populations, the clonal relationship of the Ig-expressing and nonexpressing cells was established by demonstration of identical t(14; 18) DNA rearrangements. The findings demonstrated that the variability of Ig expression in follicular lymphomas reflects the phenotypic heterogeneity of these tumors and is not a manifestation of separate clonal origins.
...
PMID:Variability of immunoglobulin expression in follicular lymphoma. An immunohistologic and molecular genetic study. 248 Jul 13
We have identified a 24-kilodalton protein that is the product of the human
bcl-2
gene, implicated as an oncogene because of its presence at the site of t(14;18) translocation breakpoints. The
Bcl-2
protein was detected by specific, highly sensitive rabbit antibodies and was shown to be present in a number of human lymphoid cell lines and tissues, as well as in mouse B cells transfected with a
bcl-2
cDNA construct. Characterization of the
Bcl-2
protein demonstrated that it has a lipophilic nature and is associated with membrane structures, probably by means of its hydrophobic carboxy-terminal membrane-spanning domain. In t(14;18)-carrying cell lines, the protein is predominantly localized to the perinuclear endoplasmic reticulum, with a minor fraction in the plasma membrane. These properties, together with the observations that
Bcl-2
does not have a characteristic signal peptide and is not glycosylated, suggest that it is an integral-membrane protein that spans the bilayer at its C-terminal hydrophobic region but is exposed only at the cytoplasmic surface. The relative abundance of the
Bcl-2
protein in various human lymphoid cell lines correlated with transcription of the
bcl-2
gene. The protein was abundant in all t(14;18)-carrying cell lines and lymphomas and was also found at lower levels in pre-B-cell lines and nonmalignant lymphoid tissues that do not carry t(14;18) translocations. These results suggest that the
Bcl-2
protein is functional in normal B lymphocytes and that a quantitative difference in its expression may play a role in the pathogenesis of lymphomas carrying the t(14;18) translocation.
...
PMID:The bcl-2 candidate proto-oncogene product is a 24-kilodalton integral-membrane protein highly expressed in lymphoid cell lines and lymphomas carrying the t(14;18) translocation. 265 3
A common feature of follicular lymphoma, the most prevalent haematological malignancy in humans, is a chromosome translocation (t(14;18] that has coupled the immunoglobulin heavy chain locus to a chromosome 18 gene denoted
bcl-2
. By analogy with the translocated c-myc oncogene in other B-lymphoid tumours
bcl-2
is a candidate oncogene, but no biological effects of
bcl-2
have yet been reported. To test whether
bcl-2
influences the growth of haematopoietic cells, either alone or together with a deregulated c-myc gene, we have introduced a human
bcl-2
complementary DNA using a retroviral vector into bone marrow cells from either normal or E mu-myc transgenic mice, in which B-lineage cells constitutively express the c-myc gene.
Bcl-2
cooperated with c-myc to promote proliferation of B-cell precursors, some of which became tumorigenic. To determine how
bcl-2
expression impinges on growth factor requirements, the gene was introduced into a lymphoid and a myeloid cell line that require interleukin 3 (IL-3). In the absence of IL-3,
bcl-2
promoted the survival of the infected cells but they persisted in a G0 state, rather than proliferating. These results argue that
bcl-2
provided a distinct survival signal to the cell and may contribute to neoplasia by allowing a clone to persist until other oncogenes, such as c-myc, become activated.
...
PMID:Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. 326 2
The patterns of expression of the
bcl-2
, bax, and bci-X genes were examined immunohistochemically in neurons of the adult rat brain before and after 10 min of global ischemia induced by transient cardiac arrest. High levels of the cell death promoting protein Bax and concomitant low levels of the apoptosis-blocking protein
Bcl-2
were found in some populations of neurons that are particularly sensitive to cell death induced by transient global ischemia, such as the CA1 sector of the hippocampus and the Purkinje cells of the cerebellum. Moreover, within 0.5 to 3 hr after an ischemic episode, immunostaining for Bax was markedly increased within neurons with morphological features of degeneration in many regions of the brain. Use of a two-color staining method for simultaneous analysis of Bax protein and in situ detection of DNA-strand breaks revealed high levels of Bax immunoreactivity in many neurons undergoing apoptosis. Postischemic elevations in Bax protein levels in the hippocampus, cortex, and cerebellum were also demonstrated by immunoblotting. At early times after transient ischemia, regulation of
Bcl-2
and Bcl-x protein levels varied among neuronal subpopulations, but from 3 hr on, those neurons with morphological evidence of degeneration uniformly contained reduced levels of Bci-2 and particularly Bci-X immunoreactivity. The findings suggest that differential expression of some members of the
bcl-2
gene family may play an important role in determining the relative sensitivity of neuronal subpopulations to ischemia and that postischemic alterations in the expression of bax,
bcl-2
, and bcl-x may contribute to the delayed neuronal cell death that occurs during the repurfusion phase after a transient ischemic episode.
...
PMID:Upregulation of bax protein levels in neurons following cerebral ischemia. 747 1
Bcl-2
and its analogs protect different classes of neurons from apoptosis in several experimental situations. These proteins may therefore provide a means for treatment of neurodegenerative diseases. We examined the effects of
Bcl-2
overexpression in a genetic mouse model with motor neuron disease (progressive motor neuronopathy/pmn). Pmn/pmn mice lose motoneurons and myelinated axons, and die at 6 weeks of age. When these mice were crossed with transgenic mice that overexpress human
Bcl-2
, there was a rescue of the facial motoneurons with a concomitant restoration of their normal soma size and expression of choline acetyltransferase. However,
Bcl-2
overexpression did not prevent degeneration of myelinated axons in the facial and phrenic motor nerves and it did not increase the life span of the animals. Since
Bcl-2
acts strictly on neuronal cell body survival without compensating for nerve degeneration in pmn/pmn/
bcl-2
mice, this proto-oncogene would not in itself be sufficient for treatment of neurodegenerative diseases where axonal impairment is a major component.
...
PMID:Bcl-2 overexpression prevents motoneuron cell body loss but not axonal degeneration in a mouse model of a neurodegenerative disease. 747 23
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>